Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 11, 2021 09:00 ET | Source: CanaQuest Medical Corp

CANAQUEST SIGNS MEDICINAL CANNABIS EDUCATION PARTNERSHIP WITH THE CANADIAN CANNABIS DISPUTE RESOLUTION CENTRE

TORONTO, March 11, 2021 (GLOBE NEWSWIRE) -- CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a Life Science/Pharmaceutical Company developing health products utilizing...
February 02, 2021 09:00 ET | Source: CanaQuest Medical Corp

CANAQUEST SIGNS MENTANINE® AND MENTABINOL® PRODUCTION AND DISTRIBUTION AGREEMENT WITH PURCANN PHARMA AND SILICYCLE INC.

TORONTO, Feb. 02, 2021 (GLOBE NEWSWIRE) -- CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a Life Science/Pharmaceutical Company developing health products utilizing...
January 19, 2021 09:00 ET | Source: CanaQuest Medical Corp

CANAQUEST PRESIDENT INTERVIEWED BY THE WALL STREET ANALYZER

TORONTO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a Life Science/Pharmaceutical Company developing health products utilizing...
December 03, 2020 09:00 ET | Source: CanaQuest Medical Corp

CANAQUEST ANNOUNCES MENTABINOL® A SCIENTIFIC DISCOVERY, AS PUBLISHED IN THE JOURNAL OF NEUROSCIENCE

TORONTO, Dec. 03, 2020 (GLOBE NEWSWIRE) -- CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a Life Science/Pharmaceutical Company developing health products utilizing...
September 17, 2020 09:00 ET | Source: CanaQuest Medical Corp

CANAQUEST MEDICAL CORP SECURES APPROVAL FOR LISTING ON THE OCMX™, AN ONLINE INVESTOR AND FINANCIAL CONNECTION PORTAL

TORONTO, Sept. 17, 2020 (GLOBE NEWSWIRE) -- CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a Life Science/Pharmaceutical Company developing health products utilizing...
July 14, 2020 11:04 ET | Source: CanaQuest Medical Corp

UPDATE: CANAQUEST MEDICAL CORP FILES PROVISIONAL PATENT FOR MENTANINE® - OMEGA-3 & PURE CANNABIDIOL (“CBD”) FORMULATION BOOSTING MENTAL HEALTH EFFICACY WHILE MINIMIZING CBD DOSAGE

TORONTO, July 14, 2020 (GLOBE NEWSWIRE) -- CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a company developing unique health products and nutraceuticals utilizing...
July 14, 2020 09:00 ET | Source: CanaQuest Medical Corp

CANAQUEST MEDICAL CORP FILES PROVISIONAL PATENT FOR MENTANINE® - OMEGA-3 & PURE CANNABIDIOL (“CBD”) FORMULATION BOOSTING MENTAL HEALTH EFFICACY WHILE MINIMIZING CBD DOSAGE

TORONTO, July 14, 2020 (GLOBE NEWSWIRE) -- CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a company developing unique health products and nutraceuticals utilizing...
February 06, 2020 09:00 ET | Source: CanaQuest Medical Corp

Canaquest Medical Corp Awaits Health Canada Approval for Sales and Export of Mentabinol®

TORONTO, Feb. 06, 2020 (GLOBE NEWSWIRE) -- CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a developer of novel health products utilizing cannabis, hemp, and botanical...
October 29, 2019 12:19 ET | Source: CanaQuest Medical Corp

CANAQUEST MEDICAL CORP is the Winner of the Go Global Awards "Business of the Year – Category of Life Science” presented by the International Trade Council

Research & development is a primary focus for this medical cannabis company TORONTO, Oct. 29, 2019 (GLOBE NEWSWIRE) -- CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or...
September 17, 2019 09:00 ET | Source: CanaQuest Medical Corp

CANAQUEST MEDICAL CORP announces filing of INTERNATIONAL CANNABIS PATENT

A NOVEL BOTANICAL AND TETRAHYDROCANNABINOL (“THC”) FORMULATION FOR THE REDUCTION OF CANNABIS-INDUCED NEGATIVE NEUROPSYCHIATRIC SIDE-EFFECTS Research & development a primary focus for this medical...

Next Page keyboard_arrow_right